Startup accelerator & VC Value proposition
Our Vision : We have High Standards - We Build Companies - We have Impact
Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).
Biotechnology, Lifesciences, Drug Development, Technology transfer, Rare diseases, Digital Healh, Diagnostics, and MedtechOriginal language
Our Vision : We have High Standards - We Build Companies - We have Impact
Kurma Partners is a key European venture capital group specialized in healthcare, with €470 million under management, with two dedicated franchises : Kurma Biofund focused on therapeutic (current active fund KBIII) and Kurma Diagnostics focused on diagnostic and digital health (current active fund Kurma Dx2).
Kurma Partners - Major player in the funding of healthcare and biotechnology in Europe
Kurma Partners - Major player in the funding of healthcare and biotechnology in Europe
https://www.kurmapartners.com/en
| Entity | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Paris-Saclay SPRING Think Tanks | Other 4 May 2018 | | |
 | SpainCap Venture Capital and Private Equity Principals | Other 3 May 2018 | | |
 | Unquote Book and Periodical Publishing | Other 21 Nov 2018 | | |
 | FUSACQ Technology, Information and Internet | Other 19 May 2022 | | |
 | Webcapitalriesgo.com Venture Capital and Private Equity Principals | Other 11 Feb 2021 | | |
 | Talent4Boards Inc. Online Audio and Video Media | Other 17 Feb 2021 | | |
 | Catalonia.Health (CataloniaBio & HealthTech) deeptech, Biotechnology Research | Other 23 Mar 2021 | | |
 | Switzerland Global Enterprise International Trade and Development | Other 25 Nov 2020 | | |
 | Dynacure biotech, deeptech, Biotechnology Research | Capitalistic Not partnership Not event 2 Apr 2020 2 Mar 2023 | | |
 | BaseLaunch Biotechnology Research | Other 2 Feb 2021 | | |